G4S plc
15 March 2021
G4S PLC
NOTIFICATION OF MAJOR SHAREHOLDING
The company was notified on 12 March 2021 by J P Morgan Chase & Co that following an acquisition of voting rights attached to shares and a change in voting rights relating to other financial instruments falling within DTR 5.3.1R (1) they hold 5.18% of the company's total voting rights.
Celine Barroche
Company Secretary
For further enquiries, please contact:
| Helen Parris | Director of Investor Relations | +44 (0) 207 9633189 |
| Media enquiries | ||
| Sophie McMillan | Head of media | +44 (0) 759 5523483 |
| Press office | +44 (0) 207 9633333 |
Notes to Editors:
G4S is the world’s leading global, integrated security company, specialising in the provision of security services and solutions to customers. Our mission is to create material, sustainable value for our customers and shareholders by being the supply partner of choice in all our markets.
G4S is quoted on the London Stock Exchange and has a secondary stock exchange listing in Copenhagen. After taking account of the businesses being sold in the year, G4S is active in around 85 countries and has around 533,000 employees. For more information on G4S, visit www.g4s.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Meltwater8.1.2026 14:00:00 CET | Press release
Meltwater Achieves SOC 2 Type II Certification, Reinforcing Commitment to Data Security and Trust
Skyharbour Resources Ltd8.1.2026 14:00:00 CET | Press release
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 662,000 Hectares in the Athabasca Basin, Saskatchewan
MoonLake Immunotherapeutics AG8.1.2026 14:00:00 CET | Press release
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Orion Oyj8.1.2026 14:00:00 CET | Press release
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Alveus Therapeutics Inc8.1.2026 13:30:00 CET | Press release
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
